immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Company profile
Ticker
IMVT
Exchange
Website
CEO
Peter Salzmann
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Health Sciences Acquisitions Corp
SEC CIK
Corporate docs
Subsidiaries
Immunovant Treasury Inc. • Immunovant Sciences Ltd. • Immunovant Sciences Holdings Limited • IMVT Corporation • Immunovant Sciences GmbH ...
IRS number
832771572
IMVT stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
12 Feb 24
8-K
Results of Operations and Financial Condition
12 Feb 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
20 Dec 23
8-K
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
28 Nov 23
S-3ASR
Automatic shelf registration
9 Nov 23
10-Q
2024 Q2
Quarterly report
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
424B5
Prospectus supplement for primary offering
29 Sep 23
8-K
Entry into a Material Definitive Agreement
28 Sep 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 269.93 mm | 269.93 mm | 269.93 mm | 269.93 mm | 269.93 mm | 269.93 mm |
Cash burn (monthly) | 20.01 mm | 11.32 mm | 19.40 mm | 21.28 mm | 20.02 mm | 17.47 mm |
Cash used (since last report) | 118.93 mm | 67.28 mm | 115.31 mm | 126.50 mm | 118.98 mm | 103.82 mm |
Cash remaining | 151.00 mm | 202.65 mm | 154.61 mm | 143.43 mm | 150.94 mm | 166.11 mm |
Runway (months of cash) | 7.5 | 17.9 | 8.0 | 6.7 | 7.5 | 9.5 |
Institutional ownership, Q2 2023
88.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 151 |
Opened positions | 30 |
Closed positions | 22 |
Increased positions | 57 |
Reduced positions | 44 |
13F shares | Current |
---|---|
Total value | 1.03 tn |
Total shares | 128.84 mm |
Total puts | 502.30 k |
Total calls | 682.70 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
ROIV Roivant Sciences | 73.40 mm | $0.00 |
Vanguard | 5.47 mm | $103.74 bn |
Deep Track Capital | 5.42 mm | $102.84 bn |
FMR | 5.25 mm | $99.67 bn |
BLK Blackrock | 4.20 mm | $79.70 bn |
STT State Street | 3.23 mm | $61.35 bn |
Perceptive Advisors | 2.52 mm | $47.88 bn |
Logos Global Management | 2.25 mm | $42.68 bn |
Avidity Partners Management | 2.09 mm | $39.55 bn |
Redmile | 1.92 mm | $36.44 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jan 24 | Michael Geffner | Common Stock | Sell | Dispose S | No | No | 38.45 | 153 | 5.88 k | 89,899 |
26 Jan 24 | Michael Geffner | Common Stock | Sell | Dispose S | No | No | 37.91 | 9,948 | 377.13 k | 90,052 |
26 Jan 24 | Mark S. Levine | Common Stock | Sell | Dispose S | No | No | 38.45 | 46 | 1.77 k | 304,102 |
26 Jan 24 | Mark S. Levine | Common Stock | Sell | Dispose S | No | No | 37.91 | 2,981 | 113.01 k | 304,148 |
18 Jan 24 | William L. Macias | Common Stock | Sell | Dispose S | No | No | 41.03 | 424 | 17.40 k | 333,173 |
11 Jan 24 | Eva Renee Barnett | Common Stock | Sell | Dispose S | No | No | 42.43 | 834 | 35.39 k | 323,350 |
11 Jan 24 | Eva Renee Barnett | Common Stock | Sell | Dispose S | No | No | 41.64 | 2,681 | 111.64 k | 324,184 |
News
Truist Securities Reiterates Buy on Immunovant, Maintains $48 Price Target
25 Mar 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Mar 24
Goldman Sachs Initiates Coverage On Immunovant with Buy Rating, Announces Price Target of $50
13 Mar 24
Wolfe Research Initiates Coverage On Immunovant with Outperform Rating, Announces Price Target of $55
15 Feb 24
Recap: Immunovant Q3 Earnings
12 Feb 24